Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies

Teng, Y K Onno; Tekstra, Janneke; Breedveld, F. C.; Lafeber, F.P.; Bijlsma, J. W. J.; Laar, Jacob M van

doi:10.1136/ard.2008.100438

Cited by 31 publications

(26 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Menopausal status was confirmed using oestradiol and follicle-stimulating hormone results. Details of the study protocol have been previously described [15]. Briefly, all patients had failed treatment with a combination(s) of disease-modifying anti-rheumatic drugs (DMARD's) and/or tumour necrosis factor (TNF) blocking agents.…”

Section: Patientsmentioning

confidence: 99%

Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Patientsmentioning

confidence: 99%

Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Patients from 2 cohorts of RA patients described previously (12,13) were included in the present study. All patients had active RA, with a Disease Activity Score evaluated in 28 joints (DAS28) of Ն3.2 (14), despite treatment with methotrexate.…”

Section: Methodsmentioning

confidence: 99%

“…Patients were given a total of 2 infusions of rituximab, one on day 1 and the other on day 15; each infusion consisted of 1,000 mg. Premedication with methylprednisolone was omitted in cohort 2, as previously described (12). In both cohorts, the DAS28 using the erythrocyte sedimentation rate (ESR) was used to evaluate disease activity.…”

Section: Methodsmentioning

confidence: 99%

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

Thurlings

Boumans

Tekstra

et al. 2010

Arthritis & Rheumatism

120

View full text Add to dashboard Cite

Objective. To analyze the relationship between the type I interferon (IFN) signature and clinical response to rituximab in rheumatoid arthritis (RA) patients.Methods. Twenty RA patients were treated with rituximab (cohort 1). Clinical response was defined as a decrease in the Disease Activity Score evaluated in 28 joints (DAS28) and as a response according to the European League Against Rheumatism (EULAR) criteria at week 12 and week 24. The presence of an IFN signature was analyzed in peripheral blood mononuclear cells by measuring the expression levels of 3 IFN response genes by quantitative polymerase chain reaction analysis. After comparison with the findings in healthy controls, patients were classified as having an IFN high or an IFN low signature. The data were confirmed in a second independent cohort (n ‫؍‬ 31). Serum IFN␣ bioactivity was analyzed using a reporter assay.Results. In cohort 1, there was a better clinical response to rituximab in the IFN low signature group. Consistent with these findings, patients with an IFN low signature had a significantly greater reduction in the DAS28 and more often achieved a EULAR response at weeks 12 and 24 as compared with the patients with an IFN high signature in cohort 2 versus cohort 1. The pooled data showed a significantly stronger decrease in the DAS28 in IFN low signature patients at weeks 12 and 24 as compared with the IFN high signature group and a more frequent EULAR response at week 12. Accordingly, serum IFN␣ bioactivity at baseline was inversely associated with the clinical response, although this result did not reach statistical significance.Conclusion. The type I IFN signature negatively predicts the clinical response to rituximab treatment in patients with RA. This finding supports the notion that IFN signaling plays a role in the immunopathology of RA.

show abstract

“…Recent data have supported fixed retreatment every 24 weeks versus ondemand retreatment (Teng et al, 2009;Mease et al, 2010).…”

Section: Targeting B Cellsmentioning

confidence: 99%

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

et al. 2011

View full text Add to dashboard Cite

Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies

Cited by 31 publications

References 5 publications

Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis

Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

Contact Info

Product

Resources

About